Guggenheim Reiterates Buy Rating on Amylyx Pharmaceuticals, Inc. (AMLX)

Market Context

Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $17.44 with a market capitalization of $1.3B.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amylyx Pharmaceuticals, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Amylyx Pharmaceuticals, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 25, 2026	Guggenheim	Buy	N/A
Apr 28, 2026	Mizuho	Outperform	N/A
Mar 25, 2026	HC Wainwright & Co.	Buy	N/A
Mar 19, 2026	Guggenheim	Buy	N/A
Mar 04, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View AMLX Stock Page